May. 19 at 7:43 PM
$AKBA $CRMD
$AKBA 2 Drugs Auryxia & Vafseo worth
$80M Today
If
$CRMD were to buy it, it needs 50% discount to satisfy Cormedix Shareholders therefore ≈
$40M (8 Times
$TLPH Size Investment)
Auryxia is Closet to Cormedix Toprol-XL (No IP Protection) valued at 1:1 Revenues, likely will stabilise around
$70M per year in 2027 onwards
Vafseo worth
$10M post TDAPA ,real value was in non-dialysis CKD, which unfortunately it failed, The dialysis CKD has no advantage over cheap generic ESAs,
$AKBA Could use the proceeds (
$40M) to fund their pipeline Praliciguat, AKB-097, AKB-9090, AKB-9090 / AKB-10108
